Get alerts of updates about «A retrospective assessment of protective GBS capsular polysaccharide levels in newborn Norwegian infants participating in the Norwegian Mother Child Cohort-Study»
You have subscribed to alerts about:
A retrospective assessment of protective GBS capsular polysaccharide levels in newborn Norwegian infants participating in the Norwegian Mother Child Cohort-Study - project description
About 1/3 of all women and men are carriers of Group B streptococci (GBS) in the urogenital tract. In connection with a vaginal birth, about half of the children of women who carry GBS will be colonized on the skin surface. However, there is also a small proportion of children who become ill with a serious GBS infection (sepsis, pneumonia, meningitis etc). These are very dreaded infections and newborns are therefore treated quite liberally with antibiotics to prevent GBS-disease. Unfortunately, the massive antibiotic treatment leads to unwanted effects on the intestinal flora and immune system of the newborn baby, and it can be troublesome for the baby. In addition, one will not always find the "right children" who need treatment. This means that some children can still become ill and die or suffer serious late injuries.
A new GBS vaccine is under development. To assess the effect of this vaccine, one also wants to look at the antibody level in the blood of newborn babies who have had GBS infection and compare it with children who have not had GBS infection. This is an important part of the evaluation of such a new vaccine. In this project, we will look at GBS antibody levels in the blood of mothers and newborns that were included in the Norwegian Mother, Father and Child Cohort Study (MoBa), both cases with infections and healthy controls.
The project will contribute to GBS vaccine development. Introduction of such a vaccine may both protect newborns against GBS infections, but also help to reduce unnecessary antibiotic treatment.